NCT03675893 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03675893
Title	RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Recruitment	Recruiting
Gender	female
Phase	Phase II
Variant Requirements	Yes
Sponsors	Dana-Farber Cancer Institute
Indications	peritoneum cancer fallopian tube carcinoma uterine carcinosarcoma ovarian serous carcinoma endometrial cancer
Therapies	Abemaciclib + LY3023414 Abemaciclib + Letrozole Abemaciclib + Letrozole + Metformin Abemaciclib + Letrozole + LY3023414 Abemaciclib + Gedatolisib + Letrozole Abemaciclib + Letrozole + Zotatifin
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST